Results 71 to 80 of about 16,133 (222)
Drug Design, Development and Therapy, 2022 Min Zhang,1 Yao Lv,2 Haokui Liu3 1Department of Nephrology, Bayannur Hospital, Bayannur, Inner Mongolia, People’s Republic of China; 2Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, People ...
Zhang M, Lv Y, Liu H
doaj
Frontiers in Genetics, 2013 Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human liver. Expression is highly variable both between individuals and within individuals, owing to nongenetic factors, genetic polymorphisms, inducibility and irreversible ...
Ulrich M Zanger, Kathrin eKlein
doaj +1 more source
Epileptic Disorders, EarlyView.Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source
Association between CYP2B6 polymorphism and acute leukemia in a Han population of Northwest China
Molecular Genetics & Genomic Medicine, 2020 Background The aim of this study was to investigate potential associations between CYP2B6 c.516G>T polymorphism and the occurrence and prognosis of acute leukemias (AL) in the Han population of Northwest China.
Li‐Li Yu, Wei Zhang, Juan Li, Li Zhao
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen +5 more
wiley +1 more source
Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz [PDF]
, 2013 The purpose of this study was to determine the demographic and pharmacogenetic covariates that influence the disposition of efavirenz (EFV) and its major metabolites.
Abdelhady, A.M. +5 more
core +1 more source
Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia
Haemophilia, EarlyView.ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh +5 more
wiley +1 more source
Common Polymorphisms ofCYP2B6Influence Stereoselective Bupropion Disposition [PDF]
Clinical Pharmacology & Therapeutics, 2018 Bupropion hydroxylation is a bioactivation and metabolic pathway, and the standard clinical CYP2B6 probe. This investigation determined the influence ofCYP2B6allelic variants on clinical concentrations and metabolism of bupropion enantiomers. Secondary objectives evaluated the influence ofCYP2C19and P450 oxidoreductase variants.
Evan D, Kharasch, Amanda, Crafford
openaire +2 more sources
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. [PDF]
, 2012 The new anti-aggregating agent prasugrel is bioactivated by cytochromes P450 (CYP) 3A and 2B6. Ritonavir is a potent CYP3A inhibitor and was shown in vitro as a CYP2B6 inhibitor.
Ancrenaz, V. +6 more
core +2 more sources
Journal of Sleep Research, Volume 34, Issue 2, April 2025.Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont +5 more
wiley +1 more source